BeOne Medicines AG
BeOne Medicines AG (6160.HK) Stock Competitors & Peer Comparison
See (6160.HK) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 6160.HK | HK$171.10 | -1.67% | 257B | 115.61 | HK$1.48 | N/A |
| 1801.HK | HK$86.10 | +0.70% | 148.2B | 162.45 | HK$0.53 | N/A |
| 2269.HK | HK$31.36 | -3.09% | 129.6B | 23.94 | HK$1.31 | N/A |
| 9926.HK | HK$133.10 | +5.30% | 122.4B | -122.11 | -HK$1.09 | N/A |
| 1177.HK | HK$5.85 | -0.68% | 104.6B | 39.00 | HK$0.15 | +1.54% |
| 1530.HK | HK$24.28 | +1.25% | 57.3B | 22.28 | HK$1.09 | +1.03% |
| 9995.HK | HK$98.85 | +4.99% | 54.4B | 67.71 | HK$1.46 | N/A |
| 3759.HK | HK$18.27 | -1.40% | 49.9B | 18.84 | HK$0.97 | +1.20% |
| 2696.HK | HK$69.65 | -2.86% | 37.9B | 40.73 | HK$1.71 | N/A |
| 2096.HK | HK$12.55 | +3.98% | 32.6B | 20.57 | HK$0.61 | +1.39% |
Stock Comparison
6160.HK vs 1801.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 1801.HK has a market cap of 148.2B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 1801.HK trades at HK$86.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 1801.HK's P/E ratio is 162.45. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 1801.HK's ROE of +0.05%. Regarding short-term risk, 6160.HK is less volatile compared to 1801.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 1801.HK's competition here
6160.HK vs 2269.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2269.HK has a market cap of 129.6B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2269.HK trades at HK$31.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2269.HK's P/E ratio is 23.94. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2269.HK's ROE of +0.11%. Regarding short-term risk, 6160.HK is less volatile compared to 2269.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2269.HK's competition here
6160.HK vs 9926.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 9926.HK has a market cap of 122.4B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 9926.HK trades at HK$133.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 9926.HK's P/E ratio is -122.11. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 9926.HK's ROE of -0.14%. Regarding short-term risk, 6160.HK is less volatile compared to 9926.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 9926.HK's competition here
6160.HK vs 1177.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 1177.HK has a market cap of 104.6B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 1177.HK trades at HK$5.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 1177.HK's P/E ratio is 39.00. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 1177.HK's ROE of +0.11%. Regarding short-term risk, 6160.HK is less volatile compared to 1177.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 1177.HK's competition here
6160.HK vs 1530.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 1530.HK has a market cap of 57.3B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 1530.HK trades at HK$24.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 1530.HK's P/E ratio is 22.28. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 1530.HK's ROE of +0.15%. Regarding short-term risk, 6160.HK is less volatile compared to 1530.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 1530.HK's competition here
6160.HK vs 9995.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 9995.HK has a market cap of 54.4B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 9995.HK trades at HK$98.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 9995.HK's P/E ratio is 67.71. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 9995.HK's ROE of +0.33%. Regarding short-term risk, 6160.HK is less volatile compared to 9995.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 9995.HK's competition here
6160.HK vs 3759.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 3759.HK has a market cap of 49.9B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 3759.HK trades at HK$18.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 3759.HK's P/E ratio is 18.84. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 3759.HK's ROE of +0.11%. Regarding short-term risk, 6160.HK is more volatile compared to 3759.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 6160.HK.Check 3759.HK's competition here
6160.HK vs 2696.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2696.HK has a market cap of 37.9B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2696.HK trades at HK$69.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2696.HK's P/E ratio is 40.73. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2696.HK's ROE of +0.26%. Regarding short-term risk, 6160.HK is less volatile compared to 2696.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2696.HK's competition here
6160.HK vs 2096.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2096.HK has a market cap of 32.6B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2096.HK trades at HK$12.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2096.HK's P/E ratio is 20.57. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2096.HK's ROE of +0.16%. Regarding short-term risk, 6160.HK is less volatile compared to 2096.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2096.HK's competition here
6160.HK vs 1877.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 1877.HK has a market cap of 32.5B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 1877.HK trades at HK$23.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 1877.HK's P/E ratio is -24.29. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 1877.HK's ROE of -0.14%. Regarding short-term risk, 6160.HK is less volatile compared to 1877.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 1877.HK's competition here
6160.HK vs 6821.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 6821.HK has a market cap of 29.3B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 6821.HK trades at HK$80.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 6821.HK's P/E ratio is 24.74. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 6821.HK's ROE of +0.06%. Regarding short-term risk, 6160.HK is less volatile compared to 6821.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 6821.HK's competition here
6160.HK vs 2617.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2617.HK has a market cap of 27.6B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2617.HK trades at HK$69.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2617.HK's P/E ratio is -102.35. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2617.HK's ROE of N/A. Regarding short-term risk, 6160.HK is less volatile compared to 2617.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2617.HK's competition here
6160.HK vs 9606.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 9606.HK has a market cap of 25.4B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 9606.HK trades at HK$288.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 9606.HK's P/E ratio is -8.63. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 9606.HK's ROE of -4.44%. Regarding short-term risk, 6160.HK is less volatile compared to 9606.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 9606.HK's competition here
6160.HK vs 1548.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 1548.HK has a market cap of 24B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 1548.HK trades at HK$11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 1548.HK's P/E ratio is -5.73. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 1548.HK's ROE of -0.13%. Regarding short-term risk, 6160.HK is less volatile compared to 1548.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 1548.HK's competition here
6160.HK vs 2315.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2315.HK has a market cap of 22.7B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2315.HK trades at HK$57.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2315.HK's P/E ratio is 116.84. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2315.HK's ROE of +0.15%. Regarding short-term risk, 6160.HK is less volatile compared to 2315.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2315.HK's competition here
6160.HK vs 9969.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 9969.HK has a market cap of 20.4B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 9969.HK trades at HK$13.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 9969.HK's P/E ratio is 31.77. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 9969.HK's ROE of +0.09%. Regarding short-term risk, 6160.HK is less volatile compared to 9969.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 9969.HK's competition here
6160.HK vs 1672.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 1672.HK has a market cap of 17.8B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 1672.HK trades at HK$16.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 1672.HK's P/E ratio is -56.10. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 1672.HK's ROE of -0.13%. Regarding short-term risk, 6160.HK is less volatile compared to 1672.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 1672.HK's competition here
6160.HK vs 2162.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2162.HK has a market cap of 17.7B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2162.HK trades at HK$60.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2162.HK's P/E ratio is -27.85. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2162.HK's ROE of -0.17%. Regarding short-term risk, 6160.HK is less volatile compared to 2162.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2162.HK's competition here
6160.HK vs 6855.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 6855.HK has a market cap of 17.3B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 6855.HK trades at HK$46.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 6855.HK's P/E ratio is -11.80. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 6855.HK's ROE of -1.24%. Regarding short-term risk, 6160.HK is less volatile compared to 6855.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 6855.HK's competition here
6160.HK vs 9688.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 9688.HK has a market cap of 15.8B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 9688.HK trades at HK$14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 9688.HK's P/E ratio is -11.21. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 9688.HK's ROE of -0.23%. Regarding short-term risk, 6160.HK is less volatile compared to 9688.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 9688.HK's competition here
6160.HK vs 9887.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 9887.HK has a market cap of 14.6B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 9887.HK trades at HK$73.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 9887.HK's P/E ratio is -53.69. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 9887.HK's ROE of N/A. Regarding short-term risk, 6160.HK is less volatile compared to 9887.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 9887.HK's competition here
6160.HK vs 1952.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 1952.HK has a market cap of 13.4B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 1952.HK trades at HK$37.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 1952.HK's P/E ratio is -37.43. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 1952.HK's ROE of -0.11%. Regarding short-term risk, 6160.HK is less volatile compared to 1952.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 1952.HK's competition here
6160.HK vs 2616.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2616.HK has a market cap of 12.8B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2616.HK trades at HK$8.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2616.HK's P/E ratio is -25.00. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2616.HK's ROE of -0.64%. Regarding short-term risk, 6160.HK is less volatile compared to 2616.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2616.HK's competition here
6160.HK vs 2142.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2142.HK has a market cap of 10.5B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2142.HK trades at HK$12.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2142.HK's P/E ratio is 17.14. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2142.HK's ROE of +0.18%. Regarding short-term risk, 6160.HK is less volatile compared to 2142.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2142.HK's competition here
6160.HK vs 2157.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2157.HK has a market cap of 9.8B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2157.HK trades at HK$5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2157.HK's P/E ratio is 31.82. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2157.HK's ROE of +0.24%. Regarding short-term risk, 6160.HK is less volatile compared to 2157.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2157.HK's competition here
6160.HK vs 2171.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2171.HK has a market cap of 9.5B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2171.HK trades at HK$17.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2171.HK's P/E ratio is -87.10. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2171.HK's ROE of -0.12%. Regarding short-term risk, 6160.HK is less volatile compared to 2171.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2171.HK's competition here
6160.HK vs 2591.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2591.HK has a market cap of 9.4B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2591.HK trades at HK$20.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2591.HK's P/E ratio is -23.19. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2591.HK's ROE of -0.40%. Regarding short-term risk, 6160.HK is less volatile compared to 2591.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2591.HK's competition here
6160.HK vs 6826.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 6826.HK has a market cap of 9.1B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 6826.HK trades at HK$22.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 6826.HK's P/E ratio is 18.52. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 6826.HK's ROE of +0.05%. Regarding short-term risk, 6160.HK is less volatile compared to 6826.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 6826.HK's competition here
6160.HK vs 2256.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2256.HK has a market cap of 8.2B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2256.HK trades at HK$12.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2256.HK's P/E ratio is 123.50. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2256.HK's ROE of +0.07%. Regarding short-term risk, 6160.HK is less volatile compared to 2256.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2256.HK's competition here
6160.HK vs 9966.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 9966.HK has a market cap of 7.7B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 9966.HK trades at HK$7.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 9966.HK's P/E ratio is -56.64. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 9966.HK's ROE of -0.06%. Regarding short-term risk, 6160.HK is less volatile compared to 9966.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 9966.HK's competition here
6160.HK vs 0775.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 0775.HK has a market cap of 6.4B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 0775.HK trades at HK$0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 0775.HK's P/E ratio is -33.50. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 0775.HK's ROE of -0.05%. Regarding short-term risk, 6160.HK is less volatile compared to 0775.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 0775.HK's competition here
6160.HK vs 1477.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 1477.HK has a market cap of 6.1B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 1477.HK trades at HK$7.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 1477.HK's P/E ratio is -20.46. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 1477.HK's ROE of -0.04%. Regarding short-term risk, 6160.HK is less volatile compared to 1477.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 1477.HK's competition here
6160.HK vs 1167.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 1167.HK has a market cap of 5.7B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 1167.HK trades at HK$7.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 1167.HK's P/E ratio is -32.82. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 1167.HK's ROE of -0.18%. Regarding short-term risk, 6160.HK is less volatile compared to 1167.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 1167.HK's competition here
6160.HK vs 2509.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2509.HK has a market cap of 4.2B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2509.HK trades at HK$18.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2509.HK's P/E ratio is -19.09. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2509.HK's ROE of -0.84%. Regarding short-term risk, 6160.HK is less volatile compared to 2509.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2509.HK's competition here
6160.HK vs 1873.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 1873.HK has a market cap of 4.2B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 1873.HK trades at HK$1.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 1873.HK's P/E ratio is 28.43. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 1873.HK's ROE of +0.04%. Regarding short-term risk, 6160.HK is less volatile compared to 1873.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 1873.HK's competition here
6160.HK vs 1875.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 1875.HK has a market cap of 4.1B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 1875.HK trades at HK$5.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 1875.HK's P/E ratio is -35.37. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 1875.HK's ROE of -0.15%. Regarding short-term risk, 6160.HK is less volatile compared to 1875.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 1875.HK's competition here
6160.HK vs 6660.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 6660.HK has a market cap of 3.7B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 6660.HK trades at HK$2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 6660.HK's P/E ratio is -11.46. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 6660.HK's ROE of -0.08%. Regarding short-term risk, 6160.HK is less volatile compared to 6660.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 6660.HK's competition here
6160.HK vs 2197.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2197.HK has a market cap of 3.6B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2197.HK trades at HK$2.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2197.HK's P/E ratio is -15.33. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2197.HK's ROE of +0.11%. Regarding short-term risk, 6160.HK is less volatile compared to 2197.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2197.HK's competition here
6160.HK vs 3880.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 3880.HK has a market cap of 3B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 3880.HK trades at HK$21.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 3880.HK's P/E ratio is 24.43. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 3880.HK's ROE of N/A. Regarding short-term risk, 6160.HK is less volatile compared to 3880.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 3880.HK's competition here
6160.HK vs 6996.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 6996.HK has a market cap of 3B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 6996.HK trades at HK$4.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 6996.HK's P/E ratio is -11.37. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 6996.HK's ROE of -0.34%. Regarding short-term risk, 6160.HK is less volatile compared to 6996.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 6996.HK's competition here
6160.HK vs 1521.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 1521.HK has a market cap of 2.2B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 1521.HK trades at HK$1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 1521.HK's P/E ratio is 110.00. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 1521.HK's ROE of +0.01%. Regarding short-term risk, 6160.HK is more volatile compared to 1521.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 6160.HK.Check 1521.HK's competition here
6160.HK vs 2181.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2181.HK has a market cap of 2.2B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2181.HK trades at HK$0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2181.HK's P/E ratio is 53.00. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2181.HK's ROE of +0.44%. Regarding short-term risk, 6160.HK is less volatile compared to 2181.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2181.HK's competition here
6160.HK vs 2179.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2179.HK has a market cap of 2B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2179.HK trades at HK$4.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2179.HK's P/E ratio is -3.15. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2179.HK's ROE of -1.37%. Regarding short-term risk, 6160.HK is more volatile compared to 2179.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 6160.HK.Check 2179.HK's competition here
6160.HK vs 3681.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 3681.HK has a market cap of 2B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 3681.HK trades at HK$1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 3681.HK's P/E ratio is -17.20. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 3681.HK's ROE of -0.28%. Regarding short-term risk, 6160.HK is less volatile compared to 3681.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 3681.HK's competition here
6160.HK vs 1541.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 1541.HK has a market cap of 1.9B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 1541.HK trades at HK$4.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 1541.HK's P/E ratio is -7.45. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 1541.HK's ROE of -0.33%. Regarding short-term risk, 6160.HK is less volatile compared to 1541.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 1541.HK's competition here
6160.HK vs 2511.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2511.HK has a market cap of 1.7B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2511.HK trades at HK$2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2511.HK's P/E ratio is -5.16. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2511.HK's ROE of -0.39%. Regarding short-term risk, 6160.HK is less volatile compared to 2511.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2511.HK's competition here
6160.HK vs 6622.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 6622.HK has a market cap of 1.6B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 6622.HK trades at HK$2.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 6622.HK's P/E ratio is -6.88. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 6622.HK's ROE of -0.13%. Regarding short-term risk, 6160.HK is less volatile compared to 6622.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 6622.HK's competition here
6160.HK vs 2487.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2487.HK has a market cap of 1.6B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2487.HK trades at HK$4.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2487.HK's P/E ratio is -3.89. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2487.HK's ROE of -0.41%. Regarding short-term risk, 6160.HK is less volatile compared to 2487.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2487.HK's competition here
6160.HK vs 6998.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 6998.HK has a market cap of 1.4B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 6998.HK trades at HK$2.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 6998.HK's P/E ratio is 39.14. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 6998.HK's ROE of +0.02%. Regarding short-term risk, 6160.HK is less volatile compared to 6998.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 6998.HK's competition here
6160.HK vs 6978.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 6978.HK has a market cap of 1.4B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 6978.HK trades at HK$2.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 6978.HK's P/E ratio is -5.79. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 6978.HK's ROE of +2.93%. Regarding short-term risk, 6160.HK is less volatile compared to 6978.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 6978.HK's competition here
6160.HK vs 9939.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 9939.HK has a market cap of 1.3B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 9939.HK trades at HK$2.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 9939.HK's P/E ratio is -6.28. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 9939.HK's ROE of -0.71%. Regarding short-term risk, 6160.HK is less volatile compared to 9939.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 9939.HK's competition here
6160.HK vs 6628.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 6628.HK has a market cap of 1.2B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 6628.HK trades at HK$2.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 6628.HK's P/E ratio is -3.63. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 6628.HK's ROE of -0.38%. Regarding short-term risk, 6160.HK is less volatile compared to 6628.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 6628.HK's competition here
6160.HK vs 1228.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 1228.HK has a market cap of 1.1B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 1228.HK trades at HK$2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 1228.HK's P/E ratio is -7.31. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 1228.HK's ROE of +0.31%. Regarding short-term risk, 6160.HK is less volatile compared to 1228.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 1228.HK's competition here
6160.HK vs 2137.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2137.HK has a market cap of 1B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2137.HK trades at HK$1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2137.HK's P/E ratio is -3.97. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2137.HK's ROE of -0.09%. Regarding short-term risk, 6160.HK is less volatile compared to 2137.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2137.HK's competition here
6160.HK vs 2898.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2898.HK has a market cap of 1B. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2898.HK trades at HK$6.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2898.HK's P/E ratio is -10.65. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2898.HK's ROE of -0.17%. Regarding short-term risk, 6160.HK is more volatile compared to 2898.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 6160.HK.Check 2898.HK's competition here
6160.HK vs 2185.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2185.HK has a market cap of 957M. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2185.HK trades at HK$4.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2185.HK's P/E ratio is -9.90. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2185.HK's ROE of -0.15%. Regarding short-term risk, 6160.HK is less volatile compared to 2185.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2185.HK's competition here
6160.HK vs 1244.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 1244.HK has a market cap of 950.5M. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 1244.HK trades at HK$3.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 1244.HK's P/E ratio is -4.97. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 1244.HK's ROE of -0.22%. Regarding short-term risk, 6160.HK is less volatile compared to 1244.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 1244.HK's competition here
6160.HK vs 2496.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2496.HK has a market cap of 800.9M. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2496.HK trades at HK$4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2496.HK's P/E ratio is -8.98. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2496.HK's ROE of +8.43%. Regarding short-term risk, 6160.HK is more volatile compared to 2496.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 6160.HK.Check 2496.HK's competition here
6160.HK vs 2126.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2126.HK has a market cap of 799.2M. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2126.HK trades at HK$1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2126.HK's P/E ratio is -1.26. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2126.HK's ROE of -0.75%. Regarding short-term risk, 6160.HK is less volatile compared to 2126.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2126.HK's competition here
6160.HK vs 2257.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 2257.HK has a market cap of 685M. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 2257.HK trades at HK$6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 2257.HK's P/E ratio is -5.03. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 2257.HK's ROE of +1.92%. Regarding short-term risk, 6160.HK is less volatile compared to 2257.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 2257.HK's competition here
6160.HK vs 0690.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 0690.HK has a market cap of 674.7M. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 0690.HK trades at HK$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 0690.HK's P/E ratio is 5.65. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 0690.HK's ROE of +0.26%. Regarding short-term risk, 6160.HK is less volatile compared to 0690.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 0690.HK's competition here
6160.HK vs 8158.HK Comparison April 2026
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 257B. In comparison, 8158.HK has a market cap of 101.9M. Regarding current trading prices, 6160.HK is priced at HK$171.10, while 8158.HK trades at HK$0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of 115.61, whereas 8158.HK's P/E ratio is 16.75. In terms of profitability, 6160.HK's ROE is +0.07%, compared to 8158.HK's ROE of +0.89%. Regarding short-term risk, 6160.HK is less volatile compared to 8158.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.Check 8158.HK's competition here